Latest Pharmaceuticals News

Page 2 of 89
Mayne Pharma will sell its international operations, including the Salisbury manufacturing site, to Evaris Pharma for $55.5 million in cash. The deal leaves the company focused entirely on its US Women’s Health, Dermatology and DistributeRx businesses, subject to ACCC approval.
Victor Sage
Victor Sage
6 Nov 2026
Viatris has lifted its 2026 guidance midpoints across revenue, adjusted EBITDA, adjusted EPS and free cash flow after a resilient third quarter. The upgrade comes alongside a US$1.65 billion Pacira acquisition and a costly manufacturing suspension in India.
Victor Sage
Victor Sage
5 Nov 2026
Zoetis lifted its full-year adjusted earnings outlook after a mixed third quarter, but US companion animal revenue fell 8% amid price sensitivity, competition and generic pressure. The animal health group also reported an 18% drop in GAAP net income and a US$89 million impairment charge.
Ada Torres
Ada Torres
5 Nov 2026
Cardinal Health has lifted its fiscal 2027 earnings outlook after a strong opening quarter, with revenue reaching US$67.5 billion and non-GAAP diluted EPS rising 28%. The healthcare distributor also completed a US$500 million share repurchase and advanced several strategic initiatives.
Ada Torres
Ada Torres
5 Nov 2026
Neuren has lifted its 2026 trofinetide income guidance to US$91 million-US$93 million after Acadia reported a 39% rise in Q3 DAYBUE sales and a US$35 million German launch milestone. Japan trial results also support a planned 2027 regulatory filing, although a launch remains subject to approval and a distribution partner.
Victor Sage
Victor Sage
5 Nov 2026
Albemarle delivered a sharp third-quarter rebound, with adjusted EBITDA reaching US$645.5 million as higher lithium pricing and productivity gains outweighed lower Energy Storage volumes. The company also raised its Specialties outlook and cut planned 2026 capital spending, while flagging weaker fourth-quarter Energy Storage results.
Victor Sage
Victor Sage
5 Nov 2026
McKesson delivered a strong fiscal second quarter, with revenue up 8% and adjusted diluted EPS rising 18%. The healthcare distributor lifted its full-year adjusted EPS guidance while expanding its specialty-care portfolio through new investments and acquisitions.
Ada Torres
Ada Torres
5 Nov 2026
Cencora delivered a stronger fiscal 2026, with adjusted earnings per share rising 12.3% and quarterly profit benefiting from the OneOncology acquisition. The healthcare distributor expects another 8% to 10% increase in adjusted EPS in fiscal 2027, while reshaping its reporting structure and lifting its dividend.
Ada Torres
Ada Torres
4 Nov 2026
Percheron Therapeutics has lodged a prospectus for up to 280 million options linked to its earlier $2.3 million placement, with the securities carrying a $0.01 exercise price and expiring in April 2028. The filing raises no meaningful cash on issue, but could provide up to $2.8 million if all options are later exercised while adding a potentially dilutive layer to the capital structure.
Victor Sage
Victor Sage
4 Nov 2026
Amgen delivered 8% third-quarter revenue growth and a 19% increase in GAAP diluted EPS, while newer medicines continued to expand. The result came alongside sharp declines in Prolia and XGEVA sales from biosimilar competition and a busy pipeline of late-stage programmes.
Victor Sage
Victor Sage
4 Nov 2026
Pfizer has lifted its 2026 revenue and adjusted earnings guidance after a quarter in which newer and acquired medicines grew strongly enough to offset steep declines in COVID-19 products. Overall revenue was flat, while reported net income fell 8%.
Victor Sage
Victor Sage
4 Nov 2026
Clever Culture Systems has secured $2.6 million to develop APAS Revolution, a smaller benchtop system aimed at pharmaceutical manufacturers not served by its existing platform. The funding combines a discounted share placement with new debt, while commercial launch is targeted for the first half of 2028.
Victor Sage
Victor Sage
3 Nov 2026

Browse the archive

Full archive